Abstract
ACP Journal Club17 January 2012Rivaroxaban reduced stroke and systemic embolism compared with warfarin in nonvalvular AFLiviu Klein, MD, MSLiviu Klein, MD, MSUniversity of California San Francisco, San Francisco, California, USA (L.K.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-156-2-201201170-02003 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationPatel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-91. https://pubmed.ncbi.nlm.nih.gov/21830957Clinical Impact RatingsCardiology: Hematology: Neurology: References1 Connolly SJ, Ezekowitz MD, Yusuf S, et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-51. [PMID: 19717844] Google Scholar2 del Zoppo GJ, Eliasziw M. New options in anticoagulation for atrial fibrillation. N Engl J Med. 2011;365:952-3. [PMID: 21830960] Google Scholar3 Eerenberg ES, Kamphuisen PW, Sijpkens MK, et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011;124:1573-9. [PMID: 21900088] Google Scholar Author, Article, and Disclosure InformationAffiliations: University of California San Francisco, San Francisco, California, USA (L.K.)This article was published at Annals.org on 3 January 2012. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoApixaban reduced stroke and systemic embolism compared with warfarin in atrial fibrillation Liviu Klein Metrics 17 January 2012Volume 156, Issue 2Page: JC1-3KeywordsAnticoagulantsAtrial fibrillationHemorrhageHemorrhagic strokeMyocardial infarctionStrokeThrombin ePublished: 17 January 2012 Issue Published: 17 January 2012 CopyrightCopyright © 2012 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
